

# Antoine Hollebecque

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8555199/publications.pdf>

Version: 2024-02-01

169  
papers

11,672  
citations

71061

41  
h-index

29127

104  
g-index

176  
all docs

176  
docs citations

176  
times ranked

17548  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 406.	1.7	11
2	Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials. <i>European Journal of Cancer</i> , 2022, 163, 98-107.	1.3	1
3	Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. <i>European Journal of Cancer</i> , 2022, 167, 42-53.	1.3	2
4	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	7.7	28
5	Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. <i>Cancer</i> , 2022, 128, 3185-3195.	2.0	10
6	Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test. <i>Cells</i> , 2022, 11, 1901.	1.8	9
7	Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100611.	0.7	0
8	Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	15
9	Patterns of progression in patients treated for immuno-oncology antibodies combination. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 221-232.	2.0	12
10	An appraisal of emerging second line therapies for metastatic colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 165-179.	1.4	2
11	Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 438-446.	3.2	21
12	Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. <i>Cancer Discovery</i> , 2021, 11, 326-339.	7.7	144
13	Hepatic arterial infusion of chemotherapy as an option in a multimodal treatment of metastatic squamous cell carcinoma of the anus. <i>European Journal of Cancer</i> , 2021, 142, 147-149.	1.3	2
14	Immunotherapy in Advanced Biliary Tract Cancers. <i>Cancers</i> , 2021, 13, 1569.	1.7	19
15	Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 401-409.	1.9	10
16	First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRRC15, in Sarcomas and Other Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3556-3566.	3.2	21
17	Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 709-718.	1.0	5
18	Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study. <i>American Journal of Hematology</i> , 2021, 96, E376-E379.	2.0	2

#	ARTICLE	IF	CITATIONS
19	Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. <i>Cancers</i> , 2021, 13, 3776.	1.7	5
20	Safety and Antitumor Activity of Î±-PD-L1 Antibody as Monotherapy or in Combination with Î±-TIM-3 Antibody in Patients with Microsatellite Instabilityâ€“High/Mismatch Repairâ€“Deficient Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 6393-6404.	3.2	29
21	Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years. <i>European Journal of Cancer</i> , 2021, 156, 217-221.	1.3	1
22	Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?. <i>Frontiers in Immunology</i> , 2021, 12, 745146.	2.2	3
23	Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 764-774.	3.2	85
24	A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 460-467.	1.9	60
25	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 242-255.	3.2	114
26	A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1229-1236.	3.2	43
27	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 137, 117-126.	1.3	16
28	First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1235-1243.	2.9	12
29	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. <i>Nature Cancer</i> , 2020, 1, 965-975.	5.7	98
30	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020, 4, 27.	2.3	16
31	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 671-684.	5.1	923
32	<i>BRAF</i> -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2466-2476.	3.2	39
33	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. <i>Cancer Medicine</i> , 2020, 9, 2643-2652.	1.3	21
34	Interventional Radiology for Colorectal Liver Metastases. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 29-37.	1.0	3
35	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. <i>Scientific Reports</i> , 2019, 9, 11610.	1.6	36
36	Efficacy of Vemurafenib in Patients With Nonâ€“Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	31

#	ARTICLE	IF	CITATIONS
37	Molecular targeted therapy of <i>BRAF</i> -mutant colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985649.	1.4	72
38	Role of image-guided biopsy and radiomics in the age of precision medicine. <i>Chinese Clinical Oncology</i> , 2019, 8, 57-57.	0.4	15
39	Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.	1.0	6
40	5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy. <i>Anti-Cancer Drugs</i> , 2019, 30, 313-317.	0.7	14
41	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1696-1707.	7.7	157
42	Systemic treatment of pancreatic cancer revisited. <i>Seminars in Oncology</i> , 2019, 46, 28-38.	0.8	81
43	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. <i>JAMA Oncology</i> , 2019, 5, 546.	3.4	366
44	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019, 25, 946-956.	3.2	96
45	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> <sup>V600E</sup> -Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 428-443.	7.7	448
46	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. <i>European Journal of Cancer</i> , 2018, 92, 1-10.	1.3	14
47	Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. <i>European Journal of Cancer</i> , 2018, 90, 83-91.	1.3	28
48	Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. <i>Annals of Oncology</i> , 2018, 29, 1304-1311.	0.6	51
49	Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. <i>Investigational New Drugs</i> , 2018, 36, 62-74.	1.2	3
50	Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 619-628.	1.2	7
51	Are phase I trials safe for older patients?. <i>Journal of Geriatric Oncology</i> , 2018, 9, 87-92.	0.5	4
52	Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e99-e107.	1.0	2
53	Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis. <i>Leukemia and Lymphoma</i> , 2018, 59, 1742-1745.	0.6	6
54	BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3477-3484.	0.8	247

#	ARTICLE	IF	CITATIONS
55	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-9.	1.5	20
56	Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?. <i>British Journal of Cancer</i> , 2018, 119, 937-939.	2.9	7
57	Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?. <i>European Journal of Cancer</i> , 2018, 103, 108-119.	1.3	18
58	Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience. <i>European Journal of Cancer</i> , 2018, 98, 17-22.	1.3	10
59	Multilayer global longitudinal strain in patients with cancer: A comparison of two vendors. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 285-296.	0.7	8
60	Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. <i>European Journal of Cancer</i> , 2018, 101, 160-164.	1.3	52
61	Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i> -mutant glioglioma. <i>Neurology</i> , 2018, 91, 523-525.	1.5	19
62	A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 1180-1191.	5.1	811
63	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4032-4032.	0.8	4
64	Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4049-4049.	0.8	9
65	MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4134-TPS4134.	0.8	4
66	Oxaliplatin desensitization after hypersensitivity reaction: A single-center experience on more than 300 procedures.. <i>Journal of Clinical Oncology</i> , 2018, 36, 610-610.	0.8	1
67	Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 816-816.	0.8	3
68	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018, 9, 9741-9750.	0.8	12
69	When Imaging Becomes Clinically Relevant: Multikinase Inhibitor-related Pancreatic Insufficiency and Pancreatic Atrophy. <i>Radiology</i> , 2017, 282, 609-610.	3.6	2
70	Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1257-1265.	1.1	25
71	Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2017, 81, 81-89.	1.3	11
72	Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?. <i>European Journal of Cancer</i> , 2017, 81, 161-173.	1.3	27

#	ARTICLE	IF	CITATIONS
73	Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1747-1750.	0.5	200
74	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. <i>Cancer Discovery</i> , 2017, 7, 586-595.	7.7	554
75	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). <i>European Journal of Cancer</i> , 2017, 84, 212-218.	1.3	132
76	Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). <i>European Journal of Cancer</i> , 2017, 84, 202-211.	1.3	29
77	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3640-3646.	0.7	25
78	Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. <i>European Journal of Cancer</i> , 2017, 83, 194-202.	1.3	14
79	Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. <i>Anti-Cancer Drugs</i> , 2017, 28, 341-349.	0.7	10
80	Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. <i>Seminars in Oncology</i> , 2017, 44, 114-128.	0.8	14
81	A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. <i>European Journal of Cancer</i> , 2017, 87, 131-139.	1.3	35
82	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. <i>European Journal of Cancer</i> , 2017, 87, 122-130.	1.3	120
83	Patient-reported tolerability of adverse events in phase 1 trials. <i>ESMO Open</i> , 2017, 2, e000148.	2.0	20
84	First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. <i>European Journal of Cancer</i> , 2017, 81, 142-150.	1.3	24
85	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. <i>Clinical Cancer Research</i> , 2017, 23, 1920-1928.	3.2	960
86	Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. <i>Investigational New Drugs</i> , 2017, 35, 79-86.	1.2	3
87	An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 2827-2835.	0.6	15
88	Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial. <i>Annals of Oncology</i> , 2017, 28, vi55.	0.6	0
89	Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. <i>BMC Cancer</i> , 2017, 17, 547.	1.1	5
90	Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC). <i>Cancer Research</i> , 2017, 77, CT074-CT074.	0.4	106

#	ARTICLE	IF	CITATIONS
91	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. Journal of Clinical Oncology, 2017, 35, 2004-2004.	0.8	1
92	A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients.. Journal of Clinical Oncology, 2017, 35, 2507-2507.	0.8	9
93	Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.. Journal of Clinical Oncology, 2017, 35, 4015-4015.	0.8	71
94	An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers.. Journal of Clinical Oncology, 2017, 35, 5504-5504.	0.8	89
95	An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).. Journal of Clinical Oncology, 2017, 35, 6025-6025.	0.8	25
96	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with <i>BRAF</i> <sup>V600</sup> mutation.. Journal of Clinical Oncology, 2017, 35, 9074-9074.	0.8	10
97	A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, TPS3626-TPS3626.	0.8	2
98	A phase IB, multicenter, open-label study to assess the safety, tolerability, and efficacy of the pleiotropic pathway modifier CC122 administered orally to patients with advanced HCC.. Journal of Clinical Oncology, 2017, 35, 379-379.	0.8	0
99	Overall survival prognosis of patients in immuno-oncology phase I trials: The Gustave Roussy score.. Journal of Clinical Oncology, 2017, 35, 3029-3029.	0.8	0
100	Evaluation of PFS ratio in patients with cancer enrolled in early-phase clinical trials: A single center, retrospective analysis.. Journal of Clinical Oncology, 2017, 35, e14025-e14025.	0.8	2
101	MET aberrations across multiple tumor types: Results of a molecular screening program (MOSCATO) Tj ETQq1 1 0.784314 rgBT /Overlo 0.8	0.8	0
102	Abstract 1011: RNAseq analysis obtained from on-purpose tumor biopsies of patients in the MATCH-R trial allows the identification of potential mechanisms of acquired resistance to PD(L)1 therapies. , 2017, , .		0
103	A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. PLoS ONE, 2016, 11, e0154895.	1.1	10
104	Patients aged over 75 years enrolled in Phase I clinical trials: the <i>G</i> ustave <i>R</i> oussy experience. International Journal of Cancer, 2016, 138, 875-880.	2.3	5
105	Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. International Journal of Cardiology, 2016, 214, 364-369.	0.8	0
106	A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Annals of Oncology, 2016, 27, 2268-2274.	0.6	108
107	Clinical efficacy of HER3 partners' inhibitors in ERBB3 mutated cancer patients. Annals of Oncology, 2016, 27, vi38.	0.6	3
108	Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?. Hepatic Oncology, 2016, 3, 109-118.	4.2	4

#	ARTICLE	IF	CITATIONS
109	Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. <i>Clinical Cancer Research</i> , 2016, 22, 2960-2968.	3.2	103
110	Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01). <i>European Journal of Cancer</i> , 2016, 59, 79-89.	1.3	36
111	Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. <i>Molecular Oncology</i> , 2016, 10, 566-574.	2.1	74
112	Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?. <i>Annals of Oncology</i> , 2016, 27, 344-352.	0.6	9
113	Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer: results of a first-in-man dose-escalation study with a fixed-dose extension phase. <i>Annals of Oncology</i> , 2015, 26, 1005-1011.	0.6	25
114	Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma. <i>Cancer Biomarkers</i> , 2015, 15, 151-156.	0.8	12
115	A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 5235-5244.	3.2	25
116	Systemic treatment of advanced hepatocellular carcinoma: From disillusion to new horizons. <i>European Journal of Cancer</i> , 2015, 51, 327-339.	1.3	63
117	Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2015, 113, 1413-1420.	2.9	18
118	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 726-736.	13.9	1,483
119	Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors. <i>Cancer Research</i> , 2015, 75, CT139-CT139.	0.4	6
120	Genomic landscape of metastatic platin-resistant urothelial cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 316-316.	0.8	0
121	Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2599-2599.	0.8	0
122	Profiles of screen-failures in phase 1 clinical trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17518-e17518.	0.8	0
123	Abstract 2401: Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial. , 2015, , .		0
124	Prognostic Factors of Tumour Cellularity in Image-Guided Biopsies: Results from a Prospective Molecular Triage Trial (Moscato). <i>Annals of Oncology</i> , 2014, 25, iv564.	0.6	0
125	Inflammatory vocal fold lesions associated with angiogenesis inhibition. <i>Head and Neck</i> , 2014, 36, n/a-n/a.	0.9	1
126	Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF). <i>Medicine (United States)</i> , 2014, 93, 138-144.	0.4	138



#	ARTICLE	IF	CITATIONS
127	Implementing precision medicine initiatives in the clinic. <i>Current Opinion in Oncology</i> , 2014, 26, 340-346.	1.1	17
128	Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. <i>Clinical Cancer Research</i> , 2014, 20, 246-252.	3.2	144
129	Dysphonia induced by anti-angiogenic compounds. <i>Investigational New Drugs</i> , 2014, 32, 774-782.	1.2	19
130	Low skeletal muscle is associated with toxicity in patients included in phase I trials. <i>Investigational New Drugs</i> , 2014, 32, 382-387.	1.2	60
131	Phase I Study of Neratinib in Combination With Temezirolimus in Patients With Human Epidermal Growth Factor Receptor 2-Dependent and Other Solid Tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 68-75.	0.8	179
132	Pharmacokinetics of pazopanib administered in combination with bevacizumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1189-1196.	1.1	17
133	A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. <i>European Journal of Cancer</i> , 2014, 50, 876-884.	1.3	29
134	Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients. , 2014, , .		11
135	A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2506-2506.	0.8	3
136	Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2509-2509.	0.8	2
137	A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2620-2620.	0.8	11
138	Final results from the phase I study expansion cohort of Debio0932, an oral HSP90 inhibitor, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2550-2550.	0.8	0
139	Axitinib in refractory colorectal metastatic cancer: A phase II study of increasing doses with dynamic contrast-enhanced ultrasonography monitoring of the response.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3638-3638.	0.8	0
140	Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2565-2565.	0.8	0
141	Genomic characterization of metastatic cisplatin-resistant samples from urothelial cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11057-11057.	0.8	0
142	Abstract 900: Computing tumor growth rate across pre- and post-treatment periods uncovers anti-tumor activity in patients treated by a pan-CDK inhibitor (BAY1000394). , 2014, , .		0
143	Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. <i>European Journal of Cancer</i> , 2013, 49, 2791-2797.	1.3	29
144	A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma. <i>Investigational New Drugs</i> , 2013, 31, 1530-1538.	1.2	22

#	ARTICLE	IF	CITATIONS
145	Tumor Assessment Criteria in Phase I Trials: Beyond RECIST. <i>Journal of Clinical Oncology</i> , 2013, 31, 395-395.	0.8	17
146	Modifying phase I methodology to facilitate enrolment of molecularly selected patients. <i>European Journal of Cancer</i> , 2013, 49, 1515-1520.	1.3	15
147	Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: A prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. <i>European Journal of Cancer</i> , 2013, 49, 431-438.	1.3	41
148	First case report of intrathecal panitumumab for treatment of meningeal carcinomatosis in an EGFR mutant lung adenocarcinoma patient. <i>Lung Cancer</i> , 2013, 80, 113-114.	0.9	4
149	Targeted therapy-induced radiation recall. <i>European Journal of Cancer</i> , 2013, 49, 1662-1668.	1.3	55
150	Inclusion of Patients With Advanced Cancer in Phase I Trials: Is This a Tool for Improving Optimism and Emotional Well-Being?. <i>Journal of Clinical Oncology</i> , 2013, 31, 817-818.	0.8	7
151	Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and Toxicity. <i>PLoS ONE</i> , 2013, 8, e77472.	1.1	104
152	Abstract B174: Baseline and procedural characteristics influencing tumor cell content on on-purpose tumor biopsies: Results from a prospective molecular triage trial (MOSCATO).. , 2013, , .		0
153	Abstract C65: First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.. , 2013, , .		0
154	Abstract A130: Joint cell-line (CCLE, Sanger) and patient (TCGA) modeling of drug sensitivity reveals novel molecular biomarkers for targeted therapy and conventional chemotherapy.. , 2013, , .		0
155	Bevacizumab-induced laryngeal necrosis. <i>Annals of Oncology</i> , 2012, 23, 276-278.	0.6	16
156	Vascular disrupting agents. <i>Current Opinion in Oncology</i> , 2012, 24, 305-315.	1.1	37
157	Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer. <i>Annals of Oncology</i> , 2012, 23, ix116-ix117.	0.6	15
158	Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 499-506.	0.8	82
159	Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. <i>Investigational New Drugs</i> , 2010, 28, 529-530.	1.2	15
160	Experience of Gemcitabine plus Oxaliplatin Chemotherapy in Patients with Advanced Biliary Tract Carcinoma. <i>Chemotherapy</i> , 2010, 56, 234-238.	0.8	15
161	Neutrophil Migration During Liver Injury Is Under Nucleotide-Binding Oligomerization Domain 1 Control. <i>Gastroenterology</i> , 2010, 138, 1546-1556.e5.	0.6	32
162	Peroxisome Proliferator-Activated Receptors in HBV-Related Infection. <i>PPAR Research</i> , 2009, 2009, 1-6.	1.1	12

#	ARTICLE	IF	CITATIONS
163	Prospective Study of the Long-Term Effects of Bariatric Surgery on Liver Injury in Patients Without Advanced Disease. <i>Gastroenterology</i> , 2009, 137, 532-540.	0.6	440
164	Infection in Patients With Severe Alcoholic Hepatitis Treated With Steroids: Early Response to Therapy Is the Key Factor. <i>Gastroenterology</i> , 2009, 137, 541-548.	0.6	305
165	Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients. <i>PLoS ONE</i> , 2009, 4, e6483.	1.1	14
166	Development of a score that predicts survival among patients with bone metastasis revealing solid tumor. <i>Supportive Care in Cancer</i> , 2008, 16, 1089-1093.	1.0	6
167	Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France. <i>Journal of Hepatology</i> , 2008, 49, 175-183.	1.8	46
168	The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. <i>Hepatology</i> , 2007, 45, 1348-1354.	3.6	598
169	The Evolution of Severe Steatosis After Bariatric Surgery Is Related to Insulin Resistance. <i>Gastroenterology</i> , 2006, 130, 1617-1624.	0.6	136